Show simple item record

dc.contributor.authorChilton, C. H.
dc.contributor.authorCrowther, G. S.
dc.contributor.authorBaines, Simon D.
dc.contributor.authorTodhunter, S. L.
dc.contributor.authorFreeman, J.
dc.contributor.authorLocher, H. H.
dc.contributor.authorAthanasiou, A.
dc.contributor.authorWilcox, M. H.
dc.date.accessioned2014-02-19T13:28:53Z
dc.date.available2014-02-19T13:28:53Z
dc.date.issued2013-10-14
dc.identifier.citationChilton , C H , Crowther , G S , Baines , S D , Todhunter , S L , Freeman , J , Locher , H H , Athanasiou , A & Wilcox , M H 2013 , ' In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection ' , Journal of Antimicrobial Chemotherapy , vol. 69 , no. 3 , pp. 697-705 . https://doi.org/10.1093/jac/dkt411
dc.identifier.issn0305-7453
dc.identifier.urihttp://hdl.handle.net/2299/12849
dc.description.abstractAbstract Objectives We investigated the in vitro activity of cadazolid against 100 Clostridium difficile isolates and its efficacy in a simulated human gut model of C. difficile infection (CDI). Methods MICs of cadazolid, metronidazole, vancomycin, moxifloxacin and linezolid were determined using agar incorporation for 100 C. difficile isolates, including 30 epidemic strains (ribotypes 027, 106 and 001) with reduced metronidazole susceptibility, 2 linezolid-resistant isolates and 2 moxifloxacin-resistant isolates. We evaluated the efficacy of two cadazolid dosing regimens (250 versus 750 mg/L twice daily for 7 days) to treat simulated CDI. Microflora populations, C. difficile total viable counts and spores, cytotoxin titres, possible emergence of cadazolid, linezolid or quinolone resistance, and antimicrobial concentrations were monitored throughout. Results Cadazolid was active against all (including linezolid- and moxifloxacin-resistant) C. difficile strains (MIC90 0.125, range 0.03–0.25 mg/L). The cadazolid geometric mean MIC was 152-fold, 16-fold, 9-fold and 7-fold lower than those of moxifloxacin, linezolid, metronidazole and vancomycin, respectively. Both cadazolid dosing regimens rapidly reduced C. difficile viable counts and cytotoxin with no evidence of recurrence. Cadazolid levels persisted at 50–100-fold supra-MIC for 14 days post-dosing. Cadazolid inhibition of enumerated gut microflora was limited, with the exception of bifidobacteria; Bacteroides fragilis group and Lactobacillus spp. counts were unaffected. There was no evidence for selection of strains resistant to cadazolid, quinolones or linezolid. Conclusions Cadazolid activity was greater than other tested antimicrobials against 100 C. difficile strains. Cadazolid effectively treated simulated CDI in a gut model, with limited impact on the enumerated gut microflora and no signs of recurrence or emergence of resistance within the experimental timeframe.en
dc.format.extent526605
dc.language.isoeng
dc.relation.ispartofJournal of Antimicrobial Chemotherapy
dc.subjectMICs
dc.subjectantimicrobial persistence
dc.subjectchemostat
dc.titleIn vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infectionen
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionMicrobiology and Biotechnology
dc.contributor.institutionBiosciences Research Group
dc.contributor.institutionCentre for Research in Mechanisms of Disease and Drug Discovery
dc.contributor.institutionDepartment of Clinical, Pharmaceutical and Biological Science
dc.contributor.institutionCentre for Future Societies Research
dc.description.statusPeer reviewed
rioxxterms.versionofrecord10.1093/jac/dkt411
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record